ZOCOR

Compare ZOCOR  to:
Compare
Compare

Generic Name for ZOCOR

Simvastatin 5mg, 10mg, 20mg, 40mg, 80mg; tabs.

Legal Classification:

Rx

Pharmacological Class for ZOCOR

HMG-CoA reductase inhibitor.

Manufacturer of ZOCOR

Merck & Co., Inc.

Indications for ZOCOR

Adjunct to diet when response to nondrug therapy is inadequate: primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Types lla and llb) to reduce elevated total-C, LDL-C, apo B and TG, and to increase HDL-C; hypertriglyceridemia (Type IV) or primary dysbetalipoproteinemia (Type III); adjunct to or when other lipid-lowering treatments for homozygous familial hypercholesterolemia are not available, to reduce total-C and LDL-C. In patients with coronary heart disease (CHD), diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease to reduce: risk of total mortality by reducing CHD death, risk of non-fatal MI and stroke, risk for undergoing myocardial revascularization procedures. Adjunct to diet to reduce total-C, LDL-C, and apo B in patients 10–17 years of age (≥1yr post-menarche) with heterozygous familial hypercholesterolemia if  LDL-C remains ≥190mg/dL, or if LDL-C remains ≥160mg/dL with either family history of premature cardiovascular disease (CVD) or if patient has at least 2 other CVD risk factors.

Adult dose for ZOCOR

≥17yrs: Initially 20–40mg once daily in the PM; if patient is high risk of CHD event: initially 40mg/day; range 5–80mg/day; monitor lipids after 4 weeks and periodically thereafter. Concomitant fibrates (eg, gemfibrozil), niacin ≥1g/day: avoid; if used, max simvastatin 10mg/day. Concomitant cyclosporine: initially simvastatin 5mg/day, max 10mg/day. Concomitant amiodarone, verapamil: max simvastatin 20mg/day. Severe renal insufficiency: initially 5mg/day, monitor closely. Homozygous familial hypercholesterolemia: 40mg once daily in the PM or 80mg/day in 3 divided doses (20mg twice daily + 40mg in the PM).

Children's dosing for ZOCOR

<10yrs: not recommended. 10–17yrs: initially 10mg once daily in the PM, may increase at 4 week intervals; range 10–40mg/day; max 40mg/day.

Contraindications for ZOCOR

Active liver disease. Unexplained, persistent elevated serum transaminases. Pregnancy (Cat.X). Nursing mothers.

Warnings/Precautions for ZOCOR

Monitor liver function at baseline, then as needed (test before increasing dose to 80mg/day, then after 3 months, and semiannually for 1st year); discontinue if AST or ALT levels of ≥3xULN persist. History of liver disease. Substantial alcohol consumption. Discontinue if myopathy or markedly elevated creatine kinase (>10xULN) levels occur. Severe renal insufficiency.

Interactions for ZOCOR

Due to increased myopathy risk: suspend simvastatin if itraconazole, ketoconazole, erythromycin, clarithromycin must be used; avoid other concomitant potent CYP3A4 inhibitors (eg, HIV protease inhibitors, nefazodone, grapefruit juice >1 quart daily); avoid gemfibrozil, other fibrates, niacin ≥1g/day, reduce max simvastatin dose if these must be used; reduce max simvastatin dose if amiodarone or verapamil must be used; reduce initial and max simvastatin doses if cyclosporine must be used. Monitor digoxin, oral anticoagulants.

Adverse Reactions for ZOCOR

Elevated serum transaminases, myopathy, rhabdomyolysis.

How is ZOCOR supplied?

Tabs 5mg, 40mg, 80mg—30, 60, 90, 1000
10mg—30, 90, 1000, 10000
20mg—30, 60, 90, 1000, 10000

Related Disease:

Dyslipidemias

Related Resources

Phase 3 trials of mipomersen for the treatment of hypercholesterolemia

August 05, 2010

Genzyme and Isis Pharmaceuticals announced results of two Phase 3 studies of patients who had high cholesterol levels while on maximally tolerated lipid-lowering therapy.

Additional dosage strengths of Simcor approved

July 29, 2010

Abbott announced that it has received FDA approval for two new dosage strengths of Simcor (niacin extended-release/simvastatin tablets).

Livalo available for primary hyperlipidemia and mixed dyslipidemia

June 21, 2010

Livalo (pitavastatin tablets) has been made available by Kowa for use in adults for the treatment of primary hyperlipidemia and mixed dyslipidemia as an adjunctive therapy to diet to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C).

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

FDA warns of increased myopathy risk with high dose Zocor

March 19, 2010

The FDA has notified healthcare professionals that there may be an increased risk of myopathy associated with the highest approved dose of Zocor (simvastatin, from Merck) 80mg, compared to lower simvastatin doses and possibly other drugs in the "statin" class.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions